My Community Journeys announced today that they recently hosted the first legal group therapy session with psilocybin mushrooms ever in North America. My Community Journeys is an independent non-profit collaborative of healthcare professionals on Vancouver Island.
NanoAlchemie, a drug delivery research company, is pleased to announce its patent application for a novel drug delivery system for psychedelic drugs, psilocybin, entheogens, and beneficial medical mushroom extracts, has been accepted by the US Patent Office.
Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Ketamine assisted therapy provider opens fourth clinic in the state of Colorado.
As demand for veteran mental health services spiked in recent months, Texas has begun to invest resources into a novel treatment for PTSD.
A single infusion of ketamine rapidly improves distorted thinking and reasoning to reduce suicidal thoughts, independent of the drug’s effect on severe depression, new research shows.
Biomind Labs Inc. is pleased to announce that Alejandro Antalich, Chief Executive Officer, and Dr. Draulio Barros de Araujo, Scientific and Clinical Advisor, will present at H.C. Wainwright 2nd Annual Psychedelics Conference on Monday, December 6, 2021.
Researchers at Vanderbilt discovered that ketamine’s antidepressant effect is due to synaptic effects. This is a new target for drug discovery that could fill a huge gap in the care for depression.
Denver was the first city in the U.S. to decriminalize psilocybin mushrooms—and two and half years after the reform was approved by voters, a panel established under the initiative is working to build upon that success.
PharmaTher announces that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle patch for the intradermal delivery of psychedelics, in delivering psilocybin.